Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT03371979. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main purpose of this Phase 1/2 study is to determine the safety and efficacy of pegzilarginase in combination with pembrolizumab in patients with ED-SCLC who have relapsed or progressive disease on or within 6 months of platinum-based chemotherapy.
Study identification
- NCT ID
- NCT03371979
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 68 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 21, 2017 (Actual)
- Primary completion
- Jan 1, 2021 (Actual)
- Completion
- Jan 1, 2021 (Actual)
- Last update posted
- Nov 4, 2021
2017 – 2021
United States locations
- U.S. sites
- 21
- U.S. states
- 15
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama, Mitchell Cancer Institute | Mobile | Alabama | 36604 | — |
| University of Colorado | Aurora | Colorado | 80045 | — |
| Rocky Mountain Cancer Centers | Denver | Colorado | 80218 | — |
| Mid Florida Hematology and Oncology Centers | Orange City | Florida | 32763 | — |
| Woodlands Medical Specialists, PA | Pensacola | Florida | 32503 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Emory University | Atlanta | Georgia | 30307 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| Nebraska Cancer Specialists | Omaha | Nebraska | 68130 | — |
| The Valley Hospital, Luckow Pavilion | Paramus | New Jersey | 07652 | — |
| Oncology Hematology Care Inc. | Cincinnati | Ohio | 45242 | — |
| Providence Cancer Center | Portland | Oregon | 97213 | — |
| UPMC Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| Charleston Hematology Oncology Associates | Charleston | South Carolina | 29414 | — |
| West Clinic | Germantown | Tennessee | 38138 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Texas Oncology-Memorial City | Houston | Texas | 77024 | — |
| Texas Oncology-Tyler | Tyler | Texas | 75702 | — |
| Oncology & Hematology Associates of SW Virginia | Blacksburg | Virginia | 24060 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03371979, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 4, 2021 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03371979 live on ClinicalTrials.gov.